Reported 5 months ago
The article discusses why the author, Alex Carchidi, would not currently recommend investing in Bristol Myers Squibb (NYSE: BMY) stock, despite its positive attributes like a high dividend yield and being a leading pharmaceutical company. The company recently revised its earnings estimates downwards significantly, and there are concerns about its high debt levels and slow growth prospects. With cost-cutting measures and debt repayment taking priority over growth initiatives, the author suggests looking elsewhere for investment opportunities.
Source: YAHOO